Collegium Pharmaceutical (COLL) EV to EBIT (2015 - 2026)

Collegium Pharmaceutical has reported EV to EBIT for 12 years, with the latest figure at 277.75 in Q2 2026.

• On a quarterly basis, EV to EBIT rose 1271.83% year-over-year to 277.75 in Q2 2026; TTM through Jun 2026 was 6.52, a 19.09% increase from a year earlier, with the FY2025 full-year figure at 6.02, up 38.58% from the prior year.
• EV to EBIT was 277.75 for Q2 2026 at Collegium Pharmaceutical, up from 21.04 in the prior quarter.
• The five-year high for EV to EBIT was 277.75 in Q2 2026, with the low at 58.31 in Q1 2022.
• Average EV to EBIT over 5 years is 32.46, with a median of 19.62 recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: EV to EBIT tumbled 289.66% in 2022, then jumped 1271.83% in 2026.
• Over 5 years, EV to EBIT stood at 52.02 in 2022, then plunged by 79.11% to 10.87 in 2023, then soared by 78.19% to 19.36 in 2024, then decreased by 8.09% to 17.8 in 2025, then surged by 1460.53% to 277.75 in 2026.
• The last three EV to EBIT figures came in at 277.75 (Q2 2026), 21.04 (Q1 2026), and 17.8 (Q4 2025), per Business Quant data.